⚠️ NOT FOR HUMAN CONSUMPTION – FOR RESEARCH PURPOSES ONLY ⚠️ ACE‑031 (Ramatercept)A soluble fusion protein based on Activin Receptor Type IIB (ActRIIB)-IgG1 Fc, designed to act as a decoy receptor for myostatin and related ligands, investigated for its potential to promote muscle growth and modulate body composition. Form: Lyophilized powder Purity: >98% (HPLC) Storage: Store in a cool, dry, and dark environment; typical long‑term storage at –20 °C(Sources: ClinicalTrials.gov – study description, UK‑Peptides – overview) Research Highlights Functions as a soluble activin receptor (ActRIIB-IgG1 Fc), binding to myostatin and other negative regulators of muscle, effectively blocking their inhibitory action on muscle development(Sources: PubMed – Phase 1 study abstract, UK‑Peptides informational overview) In a Phase 1, single ascending-dose study in healthy postmenopausal women, administration of ACE‑031 was well tolerated and led to statistically significant increases in lean body mass (~3.3%) and thigh muscle volume (~5.1%) within 29 days, along with changes in serum markers related to bone and fat metabolism(Source: PubMed – Phase 1 data) In preclinical studies involving mice, ACE‑031 treatment over four weeks resulted in substantial muscle mass gains—total body weight increased by ~16%, and specific lower limb muscles (e.g., soleus, gastrocnemius) exhibited up to ~46% weight increases—without altering muscle fiber-type distribution(Source: PubMed – preclinical study) This compound is strictly intended for laboratory research use only.It is not approved for human or veterinary use, not a dietary supplement, and must not be used to diagnose, treat, cure, or prevent any disease or condition. FOR LABORATORY USE ONLY. NOT FOR HUMAN CONSUMPTION.